A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...
In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened ...
Lululemon Athletica, Inc. is among the companies set to leave the Nasdaq 100 Index as part of the benchmark’s annual ...
Shares of Incyte Corp. rallied 3.39% to $98.64 Monday, on what proved to be an all-around grim trading session for the stock ...
As previously reported, Nasdaq announced the results of the annual reconstitution of the Nasdaq-100 Index, which will become effective prior to ...
Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback